All treatments
Treatment
Gadovist 1.0 mmol/ml solution for injection clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomised study for double-blind, placebo-controlled evaluation of BI 765845 on top of standard of care in patients with myocardial infarction
This study is testing a new medicine, BI 765845, for people who have recently had a heart attack. Researchers want to see if adding this medicine to usual care can help reduce the damage to the heart muscle. It's a key step in understanding if this new treatment could be helpful.
For: acute myocardial infarctionSlovakia · Poland · Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A seamless Phase I/II trial with an initial open-label dose escalation part and a subsequent randomised, double-blind, placebo-controlled expansion part to evaluate the safety, tolerability, and efficacy of a single dose of BI 3720931, an inhaled lentiviral vector gene therapy, in adult people with cystic fibrosis who are ineligible for CFTR modulators (LenticlairTM 1)
This study is testing a new inhaled gene therapy, BI 3720931, for adults with cystic fibrosis who can't use other treatments. It will check if the treatment is safe, how well people tolerate it, and if it improves lung function (FEV1pp).
For: Cystic fibrosisItaly · Spain · Netherlands